Abstract
This review focuses on the emerging concepts concerning the efficacy profile of biological drugs in psoriasis ranging from moderate to severe, and attempts to provide the most recent individual positioning of biologics in treating psoriasis.
Biologic agents targeting towards specific immune mediators have emerged as treatment options for patients with moderate to-severe plaque psoriasis unresponsive or intolerant to traditional systemic agents.
Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. National registries are still evolving and will provide data on safety, to help the long-term monitoring of patients with psoriasis ongoing biological treatment.
Although several biologics have demonstrated good efficacy and tolerability in short-term trials, treatment guidelines recommend them as third line therapies due to relative lack of long-term safety data, especially for those who have been commercialized recently.
Here, we have reviewed the long-term safety data obtained from National Registries, randomized controlled trials, openlabel extension studies and meta-analyses on etanercept, infliximab, adalimumab, and ustekinumab in the treatment of adults with moderate to severe plaque psoriasis.
Keywords: Psoriasis, safety profile, TNF alpha inhibitors.
Current Drug Safety
Title:Biologic Therapy in Psoriasis: Safety Profile
Volume: 11 Issue: 1
Author(s): Anna Campanati, Giulia Ganzetti, K. Giuliodori, Elisa Molinelli and A. Offidani
Affiliation:
- ,0
Keywords: Psoriasis, safety profile, TNF alpha inhibitors.
Abstract: This review focuses on the emerging concepts concerning the efficacy profile of biological drugs in psoriasis ranging from moderate to severe, and attempts to provide the most recent individual positioning of biologics in treating psoriasis.
Biologic agents targeting towards specific immune mediators have emerged as treatment options for patients with moderate to-severe plaque psoriasis unresponsive or intolerant to traditional systemic agents.
Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. National registries are still evolving and will provide data on safety, to help the long-term monitoring of patients with psoriasis ongoing biological treatment.
Although several biologics have demonstrated good efficacy and tolerability in short-term trials, treatment guidelines recommend them as third line therapies due to relative lack of long-term safety data, especially for those who have been commercialized recently.
Here, we have reviewed the long-term safety data obtained from National Registries, randomized controlled trials, openlabel extension studies and meta-analyses on etanercept, infliximab, adalimumab, and ustekinumab in the treatment of adults with moderate to severe plaque psoriasis.
Export Options
About this article
Cite this article as:
Campanati Anna, Ganzetti Giulia, Giuliodori K., Molinelli Elisa and Offidani A., Biologic Therapy in Psoriasis: Safety Profile, Current Drug Safety 2016; 11(1) . https://dx.doi.org/10.2174/1574886310666151014115532
DOI https://dx.doi.org/10.2174/1574886310666151014115532 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Nature Inspired Green Fabrication Technology for Silver Nanoparticles
Current Nanomedicine The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Keto and Exomethylene Pyranonucleosides as Antitumor Agents
Mini-Reviews in Medicinal Chemistry Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Role of Angiopoietin-like 4 (ANGPTL4), a Member of Matricellular Proteins: from Homeostasis to Inflammation and Cancer Metastasis
Current Angiogenesis (Discontinued) Development of a PBPK Model for Monoclonal Antibodies and Simulation of Human and Mice PBPK of a Radiolabelled Monoclonal Antibody
Current Pharmaceutical Design New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Growth Factors, Cytokines and Dendritic Cell Development
Current Pharmaceutical Design Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology